Equities researchers at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.
Separately, Roth Mkm reaffirmed a “buy” rating and issued a $20.00 target price on shares of Bio-Path in a research note on Monday, July 8th.
Read Our Latest Research Report on Bio-Path
Bio-Path Stock Performance
Bio-Path (NASDAQ:BPTH – Get Free Report) last released its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the firm earned ($10.60) earnings per share. On average, analysts anticipate that Bio-Path will post -6.2 EPS for the current year.
Institutional Trading of Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Recommended Stories
- Five stocks we like better than Bio-Path
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is the Shanghai Stock Exchange Composite Index?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- When to Sell a Stock for Profit or Loss
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.